FX.co ★ BriaCell Reports Positive OS Data Of Its Phase 2 Clinical Study Of Bria-IMT In Breast Cancer

Biotechnology company BriaCell Therapeutics Corp. (BCTX, BCT.V) revealed on Wednesday promising survival rates from its Phase 2 clinical trial of Bria-IMT combined with an immune checkpoint inhibitor (CPI) for advanced metastatic breast cancer patients.

The median overall survival for patients in this Phase 2 study, treated with the combination of Bria-IMT and the immune checkpoint inhibitor, stands at 15.6 months. This is significantly higher compared to the 6.7-9.3 months typically reported for similar patients in existing literature.

These patients received the same Bria-IMT formulation that is currently being used in BriaCell's ongoing Phase 3 pivotal study targeting metastatic breast cancer.

The latest findings mark a notable improvement over BriaCell's previously reported median overall survival of 13.4 months in December 2023.

The Phase 2 study included 54 heavily pre-treated metastatic breast cancer patients who received the Bria-IMT combined regimen with an immune checkpoint inhibitor. Among these 54 patients, 37 were treated with the Phase 3 formulation, and 25 patients were enrolled after COVID-19 restrictions eased, allowing full study activities to resume.

This updated data adds an additional six months of follow-up to the survival statistics initially presented at the San Antonio Breast Cancer Symposium in December 2023.